You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

ALLOPURINOL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Allopurinol patents expire, and what generic alternatives are available?

Allopurinol is a drug marketed by Accord Hlthcare, Aiping Pharm Inc, Chartwell, Endo Operations, Harman Finochem, Hetero Labs Ltd V, Indoco, Ipca Labs Ltd, Lupin Ltd, Mutual Pharm, Mylan, Northstar Hlthcare, Puracap Pharm, Purepac Pharm, Sandoz, Sun Pharm Inds Inc, Sun Pharm Industries, Superpharm, Unichem, Watson Labs, Zydus Pharms, Gland Pharma Ltd, and Hikma. and is included in thirty NDAs.

The generic ingredient in ALLOPURINOL is allopurinol sodium. There are twenty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the allopurinol sodium profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Allopurinol

A generic version of ALLOPURINOL was approved as allopurinol sodium by HIKMA on August 26th, 2004.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ALLOPURINOL?
  • What are the global sales for ALLOPURINOL?
  • What is Average Wholesale Price for ALLOPURINOL?
Drug patent expirations by year for ALLOPURINOL
Drug Prices for ALLOPURINOL

See drug prices for ALLOPURINOL

Drug Sales Revenue Trends for ALLOPURINOL

See drug sales revenues for ALLOPURINOL

Recent Clinical Trials for ALLOPURINOL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Urica Therapeutics Inc.Phase 1/Phase 2
Dana-Farber Cancer InstitutePhase 2
Eli Lilly and CompanyPhase 2

See all ALLOPURINOL clinical trials

Pharmacology for ALLOPURINOL
Medical Subject Heading (MeSH) Categories for ALLOPURINOL

US Patents and Regulatory Information for ALLOPURINOL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Watson Labs ALLOPURINOL allopurinol TABLET;ORAL 018241-002 Nov 16, 1984 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sun Pharm Industries ALLOPURINOL allopurinol TABLET;ORAL 071450-002 Jan 9, 1987 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Zydus Pharms ALLOPURINOL allopurinol TABLET;ORAL 210117-002 Oct 12, 2017 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Purepac Pharm ALLOPURINOL allopurinol TABLET;ORAL 070580-001 Apr 14, 1986 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sun Pharm Industries ALLOPURINOL allopurinol TABLET;ORAL 071450-001 Jan 9, 1987 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sandoz ALLOPURINOL allopurinol TABLET;ORAL 070269-001 Dec 31, 1985 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.